Novavax reported $95.99M in Selling and Administration Expenses for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Adma Biologics ADMA:US $ 17.67M 1.88M
Agenus AGEN:US $ 18.95M 3.02M
Astrazeneca AZN:US 3.06B 1.03B
AstraZeneca AZN:LN 3.06B 1.03B
Biocryst Pharmaceuticals BCRX:US $ 34.28M 1.1M
Dynavax Technologies DVAX:US $ 31.46M 2.66M
Genocea Biosciences GNCA:US $ 3.6M 473K
Geron GERN:US $ 6.7M 1.17M
GlaxoSmithKline GSK:LN 2.68B 227M
Mannkind MNKD:US $ 20.7M 2.03M
Merk MRK:US $ 2.3B 518M
Minerva Neurosciences NERV:US $ 3.03M 398.63K
Moderna Inc MRNA:US 268M 67M
Novartis NVS:US 3.5B 486M
Novavax NVAX:US $ 95.99M 11.78M
Pain Therapeutics PTIE:US $ 2.92M 1.19M
Peregrine Pharmaceuticals PPHM:US $ 5.82M 785K
Sarepta Therapeutics SRPT:US $ 71.84M 6.22M
Tg Therapeutics TGTX:US $ 20.61M 11.8M